Navigation Links
Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer
Date:9/28/2007

(PHILADELPHIA) Scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have discovered new molecular evidence of the role of the hormone prolactin in breast cancer. They have found that prolactin, a pituitary hormone that normally stimulates breast development and milk production, initiates a new signaling pathway that may regulate the growth and survival of breast cancer cells.

The work, which appears this month in the journal Molecular Endocrinology, identifies the protein Jak1 as playing a key part in prolactin signaling in breast cancer. Jak1, which belongs to the cell growth-promoting tyrosine kinase class of enzymes, could represent a new drug target for treating breast cancer.

In breast cancer cells, we found that Jak1 not only stimulates conventional prolactin signaling via proteins such as Stat5, but also that Jak1 recruited new signals, especially Stat3 and ERK, says Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University and principal investigator of the study. Because Stat3 and ERK typically are considered tumor-promoting, inhibitors of Jak1 may become useful in breast cancer treatment.

Receptors for prolactin, have previously been shown to promote breast cancer cell growth, survival, and differentiation, Dr. Rui explains, through signaling pathways that involve activation of such proteins as Stat5, ERK, and Akt. Prolactin is also known toactivate Stat3, which has been implicated as an oncogene involved in cancer cell growth and survival. In the current study, when Jak1 protein expression was experimentally disrupted in breast cancer cells, prolactin signaling through Stat3 and ERK was completely blocked. Signaling through Stat5 and Akt was reduced but still present.

Until now, prolactin was believed to signal only through Jak2 to mediate its effects, says Lynn Neilson, Ph.D., a postdoctoral fellow in the Department of Cancer Biology at Jefferson Medical College and first author of the study. The unexpected finding that prolactin also activates Jak1 in breast cancer points to a mechanism in cancer cells that further promotes tumor cell growth.

Dr. Ruis laboratory currently is seeking to determine the role of Jak1 in breast cancer cell growth, survival, and invasion, which will be important for establishing the potential usefulness of Jak1 as a new drug target in patients. Prolactin is secreted by the pituitary gland, and important for milk production during lactation. Receptors for this hormone are present on a majority of breast cancers. Prolactin levels in blood are relatively unaffected by menopause, and breast cancer patients are exposed to the hormone across all age groups.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson Physicians Report on Potentially Fatal Complication of Heart Attack
2. Jefferson Researchers Want to Learn If Heart Defect at Heart of Some Migraines
3. Researchers urge caution in using ear tube surgery
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Researchers identify the early makers of Neonatal Sepsis
6. OHSU Researchers Announce New Discovery
7. Researchers Identify Gene Connected To Bipolar Disorder
8. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
9. Researchers trick Alzheimers Enzyme
10. Researchers find new HIV hiding place
11. Gene researchers make Malaria-resistant mosquito
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... to Moorwick”: the adventures of a young Scottish girl yearning to see the world. ... mother of five who used her time waiting for children to finish their extracurricular activities ... It was a way to give some meaning to the hours I waited for ...
(Date:9/20/2017)... ... 2017 , ... “Monique”: is the story of Monique, whose mother’s deteriorating ... published author, Colleen Crispi, has owned four beauty salons and written a book regarding ... estate and cooking. , “The doctor’s office was only three blocks away, and ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading strategy, ... Flannery, to its strategic advisory and client development team. , In her ... clients across different industries to develop and implement market-justified strategies, modernize and transform ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , ... Innovation Awards (EIA), held this past Thursday night at The Space in Hamden. ... presented their innovative project ideas to a panel of judges for an opportunity ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
Breaking Medicine Technology: